Company Filing History:
Years Active: 2022-2025
Title: Young Woo Choi: Innovator in Pharmaceutical Composition
Introduction
Young Woo Choi is a notable inventor based in Pohang-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions aimed at combating viral infections. With a total of three patents to his name, Choi's work is paving the way for advancements in medical treatments.
Latest Patents
Choi's latest patents include a pharmaceutical composition comprising an immunoglobulin Fc-fused interleukin-7 fusion protein. This invention is designed to prevent or treat diseases caused by influenza virus A. The fusion protein, which combines the immunoglobulin Fc region with IL-7, offers protection against infections from the influenza virus A, thereby addressing diseases associated with this virus. Another significant patent involves a pharmaceutical composition that also includes an immunoglobulin Fc-fused interleukin-7 fusion protein, specifically targeting human papillomavirus-caused diseases. This composition induces a strong immune response when administered to affected areas, allowing for the prevention and treatment of diseases caused by human papillomavirus.
Career Highlights
Choi is currently associated with Genexine, Inc., a company known for its innovative approaches in biotechnology. His work at Genexine has been instrumental in advancing therapeutic solutions that leverage the body's immune response to combat viral infections.
Collaborations
Choi collaborates with several talented individuals in his field, including Moon Cheol Kang and Donghoon Choi. Their combined expertise contributes to the innovative research and development efforts at Genexine.
Conclusion
Young Woo Choi's contributions to pharmaceutical innovations highlight the importance of research in developing effective treatments for viral infections. His work continues to inspire advancements in the medical field, showcasing the potential of immunoglobulin Fc-fused proteins in therapeutic applications.